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Introduction
It has been almost 30 years since the first human nuclear recep-
tor (NR) disorders were characterized at the molecular level (Fig-
ure 1). Since then, disorders associated with genetic defects in 
20 of the 48 known human NRs have been identified (Figure 1 
and Tables 1 and 2). In this Review we provide a brief overview 
of the range of human NR-associated diseases reported to date 
and highlight some of the key pathogenic mechanisms involved 
(Figure 2A). Our focus is on well-established monogenic germline 
disorders. We will not cover the role of somatic NR variations or 
fusion genes in cancer, nor associations found in GWAS.
Thyroid hormone receptor α and β
Thyroid hormone (TH) regulates physiologic processes (e.g., skel-
etal growth, maturation of the CNS, heart rate and contractility, 
energy expenditure) via receptors (thyroid receptor α1 [TRα1], 
TRβ1, and TRβ2) encoded by separate genes (THRA/NR1A1, 
THBR/NR1A2), with differing tissue distributions: TRα1 is high-
ly expressed in the CNS, myocardium, gastrointestinal tract, and 
skeletal muscle; TRβ1 is the predominant isoform in liver and 
kidney; TRβ2 expression is restricted principally to the hypothal-
amus, pituitary, retina, and inner ear. Such divergence of receptor 
subtype expression likely mediates distinctive phenotypes associ-
ated with defective THRB or THRA.
Resistance to THβ (RTHβ), usually dominantly inherited, is 
recognized by a characteristic biochemical signature of elevated 
circulating TH and non-suppressed thyroid-stimulating hormone 
levels, reflecting central (hypothalamic-pituitary) resistance to 
TH action, together with variable resistance in peripheral tissues. 
Approximately 160 different heterozygous THRB mutations, 
localizing to the ligand-binding domain (LBD) and involving both 
TRβ2 and TRβ1 isoforms, have been identified in the disorder (1).
Affected individuals may have nonspecific symptoms or a goi-
ter, prompting thyroid function tests that suggest the diagnosis and 
are deemed to have generalized RTH (GRTH). In approximately 
15% of cases, the same biochemical picture can be associated with 
thyrotoxic features (e.g., weight loss, tremor, anxiety, tachycardia 
in adults; failure to thrive and hyperkinetic behavior in children); 
a disproportionate resistance to TH in TRβ-expressing hypothal-
amus and pituitary (PRTH), with relative retention of hormone 
sensitivity in TRα-expressing peripheral tissues, may account for 
this phenotype. GRTH and PRTH phenotypes can be associated 
with the same TRβ mutation and may even coexist within a single 
family. Other recognized features of the disorder include atten-
tion-deficit hyperactivity disorder in childhood and dyslipidemia 
and reduced bone mineral density in adults (1).
Consonant with their location, most TRβ mutations impair 
hormone binding or (rarely) coactivator recruitment and inhib-
it action of their wild-type counterparts in a dominant-negative 
manner (Figure 2B). Receptor functional regions (such as DNA 
binding, dimerization, and corepressor binding) are devoid of 
naturally occurring TRβ mutations, with RTHβ variants clustering 
within hotspots within the LBD (1). Homozygous THRB deletion 
mediated RTHβ in the first two recorded siblings with this disor-
der, who also had audiovisual abnormalities (2). Biallelic missense 
mutations were present in five other recessively inherited cases 
(3). In roughly 15% of people with biochemical features of RTHβ, 
no THRB defect can be identified; in such situations, alterations 
in co-regulators or other factors mediating TH action have been 
postulated (1). Triiodothyroacetic acid treatment, a centrally act-
ing TH analogue that lowers TH levels, can control thyrotoxic fea-
tures of the disorder.
Following the first isolation of nuclear receptor (NR) genes, genetic disorders caused by NR gene mutations were initially 
discovered by a candidate gene approach based on their known roles in endocrine pathways and physiologic processes. 
Subsequently, the identification of disorders has been informed by phenotypes associated with gene disruption in animal 
models or by genetic linkage studies. More recently, whole exome sequencing has associated pathogenic genetic variants 
with unexpected, often multisystem, human phenotypes. To date, defects in 20 of 48 human NR genes have been associated 
with human disorders, with different mutations mediating phenotypes of varying severity or several distinct conditions being 
associated with different changes in the same gene. Studies of individuals with deleterious genetic variants can elucidate 
novel roles of human NRs, validating them as targets for drug development or providing new insights into structure-function 
relationships. Importantly, human genetic discoveries enable definitive disease diagnosis and can provide opportunities 
to therapeutically manage affected individuals. Here we review germline changes in human NR genes associated with 
“monogenic” conditions, including a discussion of the structural basis of mutations that cause distinctive changes in NR 
function and the molecular mechanisms mediating pathogenesis.
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Vitamin D receptor
The principal role of the vitamin D receptor (VDR, encoded by 
NR1I1) is in the regulation of calcium and phosphate metabo-
lism with actions in the gastrointestinal tract, kidney, and bone. 
Hypocalcemia and associated symptoms (skeletal and respiratory 
muscle weakness, seizures) in the early neonatal period or infancy 
due to lack of VDR-dependent intestinal calcium absorption dom-
inates the phenotype of autosomal recessive hereditary vitamin 
D–resistant rickets (HVDRR, also known as vitamin D–dependent 
rickets type II). Rickets manifests with bone pain, growth restric-
tion, and fractures. Low circulating calcium and phosphate levels 
and raised alkaline phosphatase are associated with normal serum 
25-hydroxy but very elevated 1,25 dihydroxyvitamin D3 (calcitri-
ol) levels, secondary hyperparathyroidism, and elevated parathy-
roid hormone levels. Alopecia (patchy or total) affecting both scalp 
and body is a distinctive, non-osseous feature of the disorder.
Approximately 100 cases of HVDRR harboring approximate-
ly 45 different homozygous or compound heterozygous VDR 
mutations have been recorded: frameshift, premature-stop, and 
DNA-binding domain (DBD) mutations lead to complete loss of 
function. Additionally, approximately 20 LBD variants exhibit 
RTHα, characterized by features of hypothyroidism in select-
ed tissues, eluded discovery probably because thyroid func-
tion tests are near-normal in the disorder. Most cases have been 
identified in childhood, with features including disproportionate 
(lower segment) growth retardation, macrocephaly, dysmorphic 
features, constipation, dyspraxia, and intellectual deficit. Bio-
chemical abnormalities include low/low-normal thyroxine (T4) 
and high/high-normal triiodothyronine (T3) computing to a low 
T4/T3 ratio, variably reduced reverse T3, elevated muscle cre-
atine kinase levels, and anemia (4, 5).
Heterozygous THRA mutations disrupt TRα1 function either 
markedly or partially and inhibit wild-type receptor action in a 
dominant-negative manner via a mechanism involving enhanced 
corepressor recruitment and target gene repression (Figure 2B, Fig-
ure 3A, and ref. 5). Some THRA defects also involve the carboxy-
terminally divergent, non-hormone-binding TRα2 isoform, with 
no discernible added clinical phenotype or gain or loss of function 
attributable to the TRα2 variant (6). Consonant with resemblance 
of the RTHα phenotype to some features seen in conventional 
hypothyroidism, T4 therapy reverses metabolic abnormalities and 
improves growth, constipation, dyspraxia, and well-being.
Table 1. Pathogenic variants in classic ligand-dependent NRs associated with human genetic disorders
Receptor Original name Official name HGNC gene Ligand OMIM First reportA Number of 
cases/familiesB
Inherited Condition
TRα Thyroid hormone 
receptor-α
NR1A1 THRA THs 614450 2012 50 AD RTHα
TRβ Thyroid hormone 
receptor-β
NR1A2 THRB THs 188570 1989C > 200 AD RTH (dominant)
274300 1992 5 Autosomal recessive RTH (recessive)
VDR Vitamin D receptor NR1I1 VDR Vitamin D, 
1,25-dihydroxyvitamin D3
277440 1988D 100 to 200 Autosomal  
recessive
Vitamin D–resistant 
rickets type IIA
GR Glucocorticoid 
receptor
NR3C1 NR3C1 Cortisol 615962 1991E 10 to 50 Autosomal 
dominant, 
autosomal recessive
Glucocorticoid 
resistance
MR Mineralocorticoid 
receptor
NR3C2 NR3C2 Aldosterone 177735 1998F 50 to 100 Autosomal dominant PHA I
605115 2001 1 Autosomal  
dominant
Hypertension with 
exacerbation in 
pregnancy
ERα Estrogen receptor 
α
NR3A1 ESR1 Estradiol 615363 1994 3 Autosomal  
recessive
Estrogen resistance
AR Androgen receptor NR3C4 AR Testosterone 300068 1989G > 200 XLR AIS
312300 1991 > 200 XLR Partial androgen 
insensitivity
n.a. 1994 50 to 100 XLR Mild androgen 
insensitivity 
(infertility)
313200 1994 > 200 XLR SBMA
AYear in which point mutations in the causative gene were first published. In some situations, described in footnotes D–G, the clinical disorder or 
syndrome had been previously recognized. BNumber of sporadic cases or families with the condition, not total number of affected individuals. CRTHβ was 
first recognized in 1967. DVitamin D–resistant rickets was described in 1978. EGlucocorticoid resistance was first reported as a clinical syndrome in 1976 and 
studied further in relation to possible GR insensitivity throughout the 1980s. FPHA in infancy was first reported in 1958. Decreased aldosterone binding 
to patient cells, which suggested an MR defect, was documented in 1985. GAIS was first reported as “testicular feminization syndrome” in 1953. In the 
1960s and 1970s it was recognized as an X-linked disorder thought to be due to androgen resistance. In the 1980s reduced androgen binding to patient 
fibroblasts was shown in a subset of individuals with AIS. HGNC, HUGO Gene Nomenclature Committee; OMIM, Online Mendelian Inheritance in Man; 
XLR, X-linked recessive.
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(e.g., p160) (14). Clinical and biochemical features in individuals 
with homozygous mutations in NR3C1 are usually more severe. 
No familial activating mutations in GRα have been reported, but 
a heterozygous variant (p.Asp410His) was reported in a woman 
with features of tissue-selective glucocorticoid hypersensitivity 
(e.g., visceral obesity, dyslipidemia, type 2 diabetes [T2D], hyper-
tension) (15). This mutant receptor increased transactivation of 
glucocorticoid-responsive genes.
Mineralocorticoid receptor
The mineralocorticoid receptor (MR, encoded by NR3C2) plays a 
key role in renal sodium retention and cardiovascular endocrinol-
ogy. Pathogenic loss-of-function variants in this receptor are asso-
ciated with a renal form of mineralocorticoid resistance known 
as autosomal-dominant (or sporadic) pseudohypoaldosteronism 
type 1 (PHA I) (16, 17). Children typically present in early infan-
cy with dehydration and failure to thrive and have hyponatremia, 
hyperkalemia, and elevated aldosterone levels and plasma renin 
activity (PRA). Some infants with elevated aldosterone and PRA 
are asymptomatic. Sodium supplementation is usually required, 
but the condition improves in childhood. In contrast, the auto-
somal recessive form of PHA I, due to defects in the amiloride- 
sensitive epithelial sodium channel, is a more severe systemic 
condition that does not remit with age.
Pathogenic MR mutations include nonsense, frameshift, splice 
and missense mutations, with a potential hotspot at c.2839C>T 
(p.Arg947*). Missense mutations often affect key amino acids 
in the LBD and impair aldosterone binding and aldosterone- 
dependent transactivation (16, 18). Nuclear localization can some-
times be affected and different variants may have differential effects 
on MR-target genes (e.g., SGK1, NDRG2, GILZ, SCNN1A) (18, 19).
A gain-of-function MR variant was reported in 2000, in one 
family with early-onset hypertension (onset before the age of 
20) (20). Females also exhibited marked hypertension during 
pregnancy. The heterozygous p.Ser810Leu variant identified 
in affected family members showed mild constitutive activity 
together with inappropriate responsiveness to progesterone. The 
leucine substitution at position 810 increases van der Waals inter-
actions and lessens hydrogen bonding with steroid side groups, 
thereby enabling progesterone to bind and activate mutant MR 
(Figure 3C). Although this germline mutation is rare, it exem-
plifies how genetic variants in NRs can potentially alter ligand 
specificity; such altered ligand specificity is well recognized with 
somatic ERα variants in breast cancer or androgen receptor (AR) 
mutations in prostate cancer.
reduced ligand binding, failure to heterodimerize with retinoid X 
receptor (RXR), or selective loss of coactivator recruitment (Fig-
ure 3B); a single HVDRR case lacking a VDR mutation has also 
been described (7). In one family, a missense VDR mutation (p. 
Glu420Ala), which abolished coactivator binding and exhibited 
dominant-negative activity, mediated HVDRR in the heterozy-
gous state (8). Patients with HVDRR require oral or intravenous 
calcium therapy; high-dose vitamin D or calcitriol treatment can 
overcome the receptor defect in LBD mutation cases (7), raising 
the possibility of structure-guided design of synthetic analogues 
for treatment of a subset of HVDRR (9).
Interestingly, alopecia occurs in patients with VDR mutations 
that lead to loss of receptor expression, DNA binding, or dimeriza-
tion, but it is not a feature in cases with ligand binding or coactiva-
tor recruitment defects. This abnormality is unresponsive to cal-
citriol therapy, leading to the hypothesis that inhibition of target 
genes by unliganded, wild-type VDR maintains normal cycling of 
hair follicles, with loss of such repression mediating hair loss (Fig-
ure 2C). Supporting this notion, mutations in hairless, a known 
component of NR repression complexes, also cause an alopecia 
syndrome (atrichia with papules) (10).
Glucocorticoid receptor α
Disruption of glucocorticoid receptor α (GRα, encoded by NR3C1) 
is associated with familial glucocorticoid resistance (FGR, also 
known as generalized glucocorticoid resistance or Chrousos syn-
drome) (11, 12). This can be dominantly or recessively inherited, 
with a range of features depending on the severity of the defect 
or underlying molecular mechanism. Individuals with FGR often 
present with fatigue, but other signs of glucocorticoid insufficien-
cy are rare. Because of reduced central feedback, adrenocortico-
tropic hormone (ACTH) is elevated, increasing cortisol and partly 
compensating for glucocorticoid resistance. One consequence of 
elevated ACTH is an increase in adrenal mineralocorticoid and 
androgen production. Consequently, clinical and biochemical 
features of FGR can include hypertension, hypokalemia, and met-
abolic alkalosis as well as hirsutism, acne, male pattern baldness, 
oligomenorrhea, and infertility.
Most pathogenic missense variants in GRα are located in the 
LBD and affect glucocorticoid binding or transactivation. Patients 
or carriers with heterozygous changes tend to have a milder phe-
notype, although dominant-negative LBD variants have been 
reported (p.Ile559Asn, Ile747Met) (13, 14). LBD mutants often 
show variably reduced ligand binding affinity as well as delayed 
nuclear translocation and altered interactions with coactivators 
Figure 1. A timeline of identification of defects in 
human NR genes. The year of the first publication 
describing a monogenic disorder associated with 
each NR is shown along the x axis. The cumulative 
number of human NRs associated with a disorder 
are shown by the y axis.
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metrium, but did have evidence of androgenization. Her bone 
age was markedly delayed (>4 years), she did not have a pubertal 
growth spurt, and her bone density was reduced (z score –2.4) with 
elevated markers of osteoblastic activity. Her estradiol was very 
elevated (10-fold above normal) with elevated inhibin A and mild-
ly raised gonadotropins, and she was resistant to estrogen treat-
ment. Analysis of ESR1 revealed a homozygous missense variant 
(p.Gln375His) in the LBD that impaired estrogen responsiveness 
in cell-based assays. More recently, a description was published of 
the first known family with estrogen resistance (p.Arg394His) (24).
These reports provide important information about the role of 
ERα in humans. As expected, ERα mediates the main effects of estro-
gen on bone growth and mineralization, as well as breast and uterine 
development in females. As in ER-knockout mice, gonadotropin con-
centrations are higher in males, possibly because very high estradiol 
and inhibin A levels in females partly mediate central feedback. Final-
ly, the woman described above had no evidence of hyperinsulinemia 
or glucose intolerance, but she had a low BMI (16.6 kg/m2) and body 
fat (28%). Long-term monitoring is needed to see whether metabolic 
abnormalities develop, although the difference in BMI between the 
two individuals may be a factor influencing insulin sensitivity.
Estrogen receptor α
Estrogen receptor α (ERα, encoded by ESR1 [also referred to as 
NR3A1]) is one of the best-studied NRs in human biology. To date, 
only three genomic pathogenic variants associated with a clear phe-
notype have been reported; however, these cases do provide import-
ant insight into the role of ERα in human development and health.
The first report of a pathogenic ESR1 variant in 1994 involved 
a 28-year-old man who presented with tall stature (204 cm), pro-
longed linear growth, delayed epiphyseal fusion, and reduced bone 
mineral density (z score –3.1) (21, 22). He had normal puberty, but 
had elevated levels of follicle-stimulating hormone and luteinizing 
hormone and reduced sperm viability. He also had impaired glu-
cose tolerance, hyperinsulinemia, and an abnormal lipid profile 
with evidence of early coronary atherosclerosis, although his BMI 
was elevated (30.5 kg/m2). Genetic analysis revealed a homozy-
gous stop gain variant (p.Arg157*). He had mildly elevated serum 
estradiol and resistance to estrogen treatment.
In 2013, the first female with estrogen resistance was report-
ed (23). This 18-year-old woman presented with absent breast 
development, primary amenorrhea, and abdominal pain due to 
hemorrhagic ovarian cysts. She had a small uterus with no endo-
Figure 2. Molecular mechanisms of disrupted NR action. (A) Mechanisms whereby NR gene and protein changes can alter function. Gene deletion or 
mutations causing mRNA instability or impairing key cellular functions can cause loss of function (left). Gain of receptor function may occur due to 
duplication of an NR genomic locus (e.g., NR0B1) or LBD mutation (right). (B) In several disorders heterozygous receptor mutants (e.g., TRβ, TRα, PPARγ, 
VDR) inhibit the action of their wild-type counterparts in a dominant-negative manner. In contrast to the wild-type receptor, either defective binding of 
ligand (L) or recruitment of coactivator (CoA) by a mutant (MUT) receptor impairs its dissociation of corepressor (CoR), mediating constitutive repression 
of target gene expression. HRE, hormone response element. (C) Alopecia is not a universal feature of hereditary vitamin D resistance. It is associated with 
VDR mutations that disrupt DNA binding, that cause loss of heterodimerization with RXR, or that cause loss of receptor expression, but not with variants 
exhibiting impaired ligand binding affinity or coactivator recruitment. Repression of target genes by unliganded wild-type receptor maintains a normal hair 
growth cycle, and the loss of such inhibition that accompanies a subset of VDR mutants (right) is thought to mediate this variable phenotype.
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quent investigations show an absent uterus, 
46,XY karyotype, and elevated testosterone 
concentrations. Breast development usually 
occurs in adolescence due to the aromatiza-
tion of androgens to estrogens, but andro-
gen-dependent pubic hair is often absent or 
sparse. Occasionally the diagnosis is made 
when testes are found during hernia repair 
in childhood or with karyotype analysis for 
another indication. As with most conditions, 
a spectrum of phenotypes can occur. Partial 
AIS (PAIS) typically presents with atypical 
genitalia or hypospadias in the newborn peri-
od, and gynecomastia is a common feature at 
adolescence in boys with this condition (27). 
Mild AIS (MAIS) has also been reported in 
men with oligospermic infertility (28).
More than 800 different pathogen-
ic variants in the AR have been reported. 
These changes include stop-gain, frame-
shift, and missense variants that are distrib-
uted throughout the gene and have been 
reviewed extensively elsewhere (26, 29, 30). 
Missense variants tend to affect important 
amino acids involved in DNA binding or 
ligand interactions, but many different resi-
dues can be affected. Although some muta-
tions associate more with complete or partial 
phenotypes, there can be overlap between 
the type and location of the change, its activ-
ity in in vitro assays, and the degree of andro-
gen insensitivity in affected individuals. 
Missense mutations in the hydro phobic ligand- 
binding pocket of the LBD usually cause 
CAIS (26), while missense mutations in the 
large aminoterminal activation function do-
main (AF-1) usually cause PAIS or MAIS. Of 
note, a subset of individuals thought to have 
AIS do not have variants in the AR gene, even 
though cultured genital fibroblasts show 
androgen resistance in vitro (e.g., reduced 
dihydrotestosterone-induced apolipopro-
tein D expression) (31). Disruption of AR- 
dependent cofactors or post-receptor signal-
ing mechanisms have been proposed as the 
cause (AIS type II) (31).
The AR is unusual in that it has a variable 
number of polyglutamine and polyglycine 
repeats in the aminoterminal region of the 
receptor. Expansion of the polyglutamine 
tract (to 38–65 CAG trinucleotide repeats) is 
associated with X-linked spinal and bulbar muscular atrophy (SBMA, 
also known as Kennedy disease) (32). This condition results from AR- 
polyglutamine toxicity; the mutant protein misfolds and aggregates 
in spinal cord motor neurons and muscle cells. SBMA can some-
times be associated with reduced androgen action, gynecomastia, 
low sperm count, and testicular atrophy (33).
AR
Disruption of the AR (encoded by NR3C4) results in androgen 
insensitivity syndrome (AIS) (25). This X-linked condition was first 
reported in 1953 and has historically been called “testicular femini-
zation syndrome” (26). Women with complete AIS (CAIS) typically 
present during late adolescence with primary amenorrhea. Subse-
Figure 3. Structural modeling of NR mutations.(A) Modeling (PDB 2H77 TRα, PDB 1KKQ SMRT) 
shows that mutation of residues (red spheres) in the carboxyterminal region of TRα, which prema-
turely truncate helix 11 or 12 (left), facilitate its ability to accommodate corepressor (SMRT, blue) with-
in a groove at the receptor surface (right). (B) Modeling (PDB 1RK3, VDR bound to DRIP 205 coactiva-
tor) shows that a glutamic acid residue (left; red sphere) hydrogen bonds with the peptide backbone 
of coactivator (middle; green). Mutation to lysine abolishes this interaction (right).(C) Modeling (PDB 
5HCV MR, PDB 5L7E S810L mutant MR) shows that wild-type receptor, with serine at position 810, 
accommodates aldosterone via hydrogen bonding with steroid (middle; red dotted line), whereas 
mutant MR with a leucine substitution accommodates progesterone via van der Waals interaction 
with steroid (right; blue dotted line). (D) Modeling (PDB 2FF0) shows SF-1/NR5A1 bound to DNA. R92 
makes an extensive hydrogen bond network in the minor groove to support monomeric binding. This 
interaction is disrupted by the R92W mutation due to the presence of an indole side group.
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Table 2. Pathogenic variants in orphan or non-classic NRs associated with human genetic disorders
Receptor Original name Official 
name
HGNC gene Ligand OMIM 
phenotype 
number
First 
report
Number of 
individuals/
families
Inherited Condition
SF-1 Steroidogenic factor-1 NR5A1 NR5A1 Orphan 612965 1999 2 Autosomal dominant, 
autosomal recessive
Primary adrenal insufficiency 
and gonadal dysgenesis 
(46,XY)
612965 2003 100–200 Autosomal dominant, 
autosomal recessive, SLD
46,XY DSD
612964 2009 10–50 Autosomal dominant, 
autosomal recessive
POI
613957 2010 10–50 Autosomal dominant Male factor infertility
n.a. 2016 10–50 Autosomal dominant 46,XX ovotesticular/testicular 
DSD
n.a. 2000 2 Autosomal dominant, 
autosomal recessive
Primary adrenal insufficiency 
(46,XX)
DAX-1 Dosage-sensitive sex reversal–
adrenal hypoplasia congenita 
critical region on the X 
chromosome, gene 1
NR0B1 NR0B1 Orphan 300200 1994A >200 XLR X-linked adrenal hypoplasia 
(with hypogonadotropic 
hypogonadism, male infertility)
300018 1991 10–50 Duplication 46,XY DSD
RARβ Retinoic acid receptor-β NR1B2 RARB Retinoic acid 615524 2013 4 Autosomal dominant, 
autosomal recessive
Syndromic microophthalmia 
(type 12), diaphragmatic 
hernia, pulmonary hypoplasia, 
cardiac defects
RORγ RAR-related orphan receptor γ NR1F3 RORC Orphan 616622 2015 3 Autosomal recessive Immunodeficiency type 42
PNR Photoreceptor-specific nuclear 
receptor
NR2E3 NR2E3 Orphan 268100 2000B 50–100 Autosomal recessive ESCS, including Goldman-Favre 
syndrome
611131 2007 10–50 Autosomal dominant, 
autosomal recessive
RP type 37
COUP-TFI Chicken ovalbumin upstream 
promoter transcription factor I
NR2F1 NR2F1 Orphan 615722 2014 10–50 Autosomal dominant Bosch-Boonstra-Schaaf 
optic atrophy syndrome 
(developmental delay)
COUP-TFII Chicken ovalbumin upstream 
promoter transcription factor II
NR2F2 NR2F2 Orphan 615779 2014 10–50 Autosomal dominant Congenital heart defects, 
multiple (type 4)
Rev-erb-β Rev-erb-β NR1D2 NR1D2 Orphan n.a. 2016 1 Autosomal dominant Congenital heart defects  
(e.g., AVSD)C
ERRβ Estrogen-related receptor β NR3B2 ESRRB Orphan 608565 2008 <10 Autosomal recessive Autosomal-recessive deafness 
type 35
FXRα Farsenoid X receptor α NR1H4 NR1H4 Bile acids 617049 2007 <10 Autosomal recessive ICP, PFIC
HNF4α Hepatocyte nuclear factor 4α NR2A1 HNF4A Orphan 125850 1996D 100–200 Autosomal dominant MODY type 1, HH
616026 2014 1 Autosomal dominant Fanconi renotubular syndrome 
type 4 with MODY
PPARγ Peroxisome proliferator 
activated receptor-γ
NR1C3 PPARG Fatty acids, 
eicosanoids
604367 1999 10–50 Autosomal dominant Familial partial lipodystrophy 
type 3, digenic severe IR
601665 1998 1 Autosomal dominantE Severe obesity
125853 1998 1 Autosomal dominant Resistance to T2D
SHP Small heterodimeric partner NR0B2 NR0B2 Orphan 601665 2001 10–50 Autosomal dominant Mild obesity, high birth weight, 
T2D
AX-linked AHC causing “cytomegalic” adrenal hypoplasia was first reported in 1948 and the X-linked basis identified in the 1970s, followed by reports 
of gene deletion syndromes involving chromosome Xp21 in the 1980s. BESCS was first described in 1990. In 1995 it was thought to be a disorder of 
photoreceptor determination and proliferation. CThe association of mutations in Rev-erb-β (NR1D2) with congenital heart defects is currently based on a 
single case report. DMODY was first recognized in 1975. EInheritance patterns are tentative, especially when only one individual or family has been reported. 
n.a., not available; SLD, sex-linked dominant;.
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Steroidogenic factor-1
Steroidogenic factor-1 (SF-1, encoded by NR5A1) was identified fol-
lowing the search for a common regulator of steroidogenic enzyme 
transcription (34, 35). Complete deletion of Nr5a1 in the mouse 
resulted in adrenal agenesis, gonadal (testicular) dysgenesis with 
persistent Müllerian structures (in the uterus and upper vagina) in 
XY animals and variable defects in gonadotropin release, confirm-
ing SF-1 as a key player in adrenal and gonad biology (36). Subse-
quently, other metabolic features such as late-onset obesity and 
ventromedial hypothalamic abnormalities were reported (37, 38).
The first descriptions of pathogenic loss-of-function variants in 
NR5A1 in humans were published in 1999 and 2002 (39, 40). These 
reports included two 46,XY girls with testicular dysgenesis, Mülle-
rian structures, and salt-losing primary adrenal insufficiency. The 
first child had a de novo heterozygous change (p. Gly35Glu) in the 
P-box region of the SF-1 DBD that affected binding to and transcrip-
tional activation of target gene response elements (39). Functional 
studies suggested this was largely a gene dosage–dependent com-
petitive effect, although partial dominant negativity was reported 
in some systems. The second child had a homozygous pathogenic 
change (p. Arg92Gln) affecting the A-box region of SF-1 DBD (40). 
SF-1 belongs to a small subgroup of NRs that bind to DNA as mono-
mers rather than as homo- or heterodimers. The A-box region is 
involved in stabilizing monomeric binding through an interaction 
with the DNA minor groove. Thus, a heterozygous P-box change 
and homozygous A-box change may have similar phenotypes.
The past decade has seen great increases in the number of 
reported pathogenic changes in NR5A1 and also the spectrum of 
SF-1–associated conditions (41). More than 200 individuals and 
families are now described in the literature. Heterozygous loss-of-
function variants in NR5A1 occur in approximately 15% of individ-
uals with testicular dysgenesis and reduced androgen production, 
resulting in 46,XY differences in/disorders of sex development 
(DSDs) (42). Phenotypes can range from females with a 46,XY 
karyotype to boys with penoscrotal hypospadias or undescended 
testes. Milder variants in NR5A1 can be associated with a small 
subset of male factor infertility, sometimes with progressive endo-
crine dysfunction (43). Variants in NR5A1 are also associated with 
primary ovarian insufficiency (POI) in 46,XX women, although 
the age of onset and natural time course are highly variable (44). 
Although many variants occur de novo, around 30% can be car-
ried and maternally transmitted as a sex-limited dominant trait. 
Because multiple members of a family may have 46,XY DSD 
with 46,XX females being at risk of POI, careful family history 
and counseling is important. Very rarely, mutations in NR5A1 can 
cause primary adrenal insufficiency in 46,XX girls.
Although true gain-of-function variants in SF-1 have not been 
reported, recent observations suggest that recurrent, heterozy-
gous missense changes in codon 92 (p.Arg92Trp, p.Arg92Gln) of 
NR5A1 are associated with ovotestes or testes in individuals with 
a 46,XX karyotype (45). Several individuals or families of diverse 
genetic ancestry have been reported. This particular amino acid 
change may interfere with expression of DAX-1 (dosage-sensitive 
sex reversal–adrenal hypoplasia congenita (AHC) critical region 
on the X chromosome, gene 1; see below) through WNT signaling 
in the developing gonad, but the exact mechanism that “switches” 
the ovary into a testis remains unclear (Figure 3D).
DAX-1
DAX-1 (encoded by NR0B1) is an orphan NR that lacks the typical 
NR DBD but that has an aminoterminal region motif comprising 
three 66–67 amino acid tandem repeats. Similar to SF-1, DAX-1 
plays a key role in adrenal and reproductive development.
DAX-1 disruption was first reported to cause X-linked AHC in 
1994 (46, 47). Since then, more than 200 individuals or families 
have been reported to have pathogenic variants in NR0B1 (41). The 
classic features in males include primary adrenal insufficiency in 
early infancy or childhood, delayed or arrested puberty due to dis-
ordered gonadotropin release, and impaired spermatogenesis.
Nonsense or frameshift variants in NR0B1 occur throughout 
the gene, whereas pathogenic missense variants tend to cluster in 
key areas of the ligand-like binding domain in regions that form the 
hydrophobic core of the protein (48). Few missense changes in the 
aminoterminal repeat structure of DAX-1 have been reported. Partial 
loss-of-function missense variants can be associated with a milder 
phenotype of delayed onset adrenal insufficiency in early adulthood, 
or partial hypogonadotropic hypogonadism (49). Surprisingly, mild-
er phenotypes can also occur due to stop gain variants at the start of 
the protein (p. Trp37*, p.Trp39*); this effect is likely due to re-initia-
tion of translation of a truncated DAX-1 protein from a downstream 
methionine at codon 83 that remains partially functional (due to the 
repeat motif structure) and “rescues” the phenotype (50).
Although DAX-1–associated conditions are well established, 
the exact biological role of DAX-1 remains unclear. Many studies 
demonstrate that DAX-1 acts as a transcriptional repressor, poten-
tially through a direct interaction with SF-1 (48). Indeed, duplica-
tion of the locus containing DAX-1 is associated with testicular 
dysgenesis, suggesting that it may act as an “anti-testis” gene. 
DAX-1 may play a role in regulating progenitor cell differentiation. 
Loss of DAX-1–dependent repression may result in premature dif-
ferentiation of progenitor cells without appropriate expansion of 
cell numbers, ultimately resulting in tissue hypoplasia. Indeed, 
loss of DAX-1 can sometimes be associated with early puberty 
in humans, and transient adrenal hyperresponsiveness has been 
reported in Dax1 knockout mice (51). Whether these phenomena 
reflect the true biological basis of DAX-1 function is still unclear.
Retinoic acid receptor-β
Retinoic acid receptor-β (RARB, encoded by NR1B2) is expressed 
in many tissues during development, and deletion of Nr1b2 in 
mice causes multiple defects (e.g., CNS, vision, hearing, mus-
culoskeletal, cardiovascular, gastrointestinal, pulmonary, renal) 
and high lethality.
In 2013, the first pathogenic RARB variants were reported in 
patients with STRA6 mutation-negative syndromic microphthal-
mia and additional features such as pulmonary hypoplasia/agen-
esis, diaphragmatic hernia/eventration, anophthalmia/microph-
thalmia, and cardiac defects (PDAC syndrome). In one family, two 
siblings were found to be compound heterozygous for disruptive 
variants (p.Arg119*/p.Ile403SerfsTer15) (52). At least three oth-
er unrelated children with microphthalmia and one or more of 
these additional features have been found to carry de novo het-
erozygous changes affecting an arginine hotspot at codon 387 
(e.g., p.Arg387Ser, p.Arg387Cys), potentially mediating a gain-of- 
function mechanism (52, 53). Taken together, these findings pro-
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and may be associated with a more severe phenotype (66, 67). 
Other features reported recently include hypotonia, oromotor 
dysfunction, thinning of the corpus callosum, seizures, autism 
spectrum disorder, and hearing impairment (67).
COUP-TFII
COUP-TFII (encoded by NR2F2) plays a role in angiogenesis, 
vascular remodeling, and heart development as well as in more 
widespread regulation of cell fate during embryonic development. 
Recently, heterozygous variants in NR2F2 have been reported 
in patients with a range of congenital cardiac disease pheno-
types (68). In one family, a 3-bp duplication in NR2F2 segregated 
with multiple cardiac defects (i.e., atrioventricular septal defect 
[AVSD], aortic stenosis/VSD, and tetralogy of Fallot), whereas oth-
er heterozygous missense mutations or deletions of NR2F2 have 
been associated with AVSD, hypoplastic left heart syndrome, or 
aortic coarctation (68). Congenital diaphragmatic hernia may be 
an association in mice and humans (69).
Rev-erb-β
Rev-erb-β (encoded by NR1D2) has several proposed actions 
including being a potential repressor of gene transcription. 
Recently, a de novo heterozygous mutation in NR1D2 was found 
in one individual with congenital heart disease (AVSD) (70). This 
variant (p.Arg175Trp) affects binding to the DNA minor groove 
and impairs transcriptional repression (70). Detailed analysis of 
Nr1d2–/– mice indicated a similar phenotype (70). As this is a very 
recent observation, the true contribution of Rev-erb-β to develop-
mental heart defects is not yet known.
Estrogen-related receptor β (NR3B2)
Estrogen-related receptor β (ERRβ, encoded by NR3B2) has struc-
tural homology to the ERs and binds ER response elements but is 
not activated by estrogens. ERRβ plays a role in placental devel-
opment and is expressed in several tissues such as the inner ear 
during development and postnatal life (71). Homozygous disrup-
tion of ESRRB was first reported in a large consanguineous Turk-
ish family with autosomal-recessive nonsyndromic hearing loss 
(type 35) (72). Homozygous point mutations in the DBD and, more 
often, in the “ligand”-binding domain of ERRβ have also been 
reported as a rare cause of nonsyndromic hearing loss, often in 
consanguineous families (72). A potential link between disruption 
of ESRRB and dental caries has also been proposed (73).
Farnesoid X receptor
Farnesoid X receptor (FXR, encoded by NR1H4), a bile acid– 
activated NR, is a key mediator of bile acid homeostasis, regulat-
ing target genes that mediate hepatic export (e.g., bile salt export 
pump [ABCB11], multidrug resistance protein 3 [ABCB4]), bio-
synthesis (e.g., CYP7A), or enterohepatic circulation (e.g., NTCP, 
IBABP) of bile acids, limiting their intrinsic hepatocellular toxicity.
Four different heterozygous NR1H4 variants (–1G>T, p.Met-
1Val, p.Trp80Arg, and p.Met173Thr) that reduce its expression or 
transcriptional activity were identified by screening 92 women 
with intrahepatic cholestasis of pregnancy (ICP), a disorder char-
acterized by late gestational pruritus and abnormal maternal and 
fetal liver function, predisposing to fetal distress and prematurity 
vide support for retinoic acid pathways in human eye development 
and organogenesis. Indeed, NR1B2 is highly expressed in the 
human retina, unlike NR1B1 or NR1B3 (54).
RAR-related orphan receptor γ
RAR-related orphan receptor γ (RORγ, encoded by RORC [also 
known as NR1F3]) plays a key role in thymocyte development and 
function, including differentiation of the Th17 cell subset. Recent-
ly, homozygous pathogenic variants in RORC, causing disruption 
of both the ROR-γ and ROR-γ–t isoforms, have been reported in 
seven individuals from three unrelated consanguineous pedigrees 
with immunodeficiency (55). These families — from Palestine, 
Chile, and Saudi Arabia — have evidence of chronic mucocutane-
ous candidiasis (due to IL-17A and IL-17F deficiency) combined 
with susceptibility to mycobacterial disease and disseminated 
infections following Bacillus Calmette-Guérin vaccines. Patients 
also all had a small thymus.
Photoreceptor-specific NR
Photoreceptor-specific NR (PNR, encoded by NR2E3) is involved 
in retinal photoreceptor cell differentiation and degeneration, 
and its disruption results in retinal degeneration in the rd7 mouse. 
Pathogenic variants in NR2E3 cause enhanced S-cone syn-
drome (ESCS) (56), an inherited retinal disorder characterized 
by increased visual function of the minority S (blue) cones and 
decreased L/M (red/green) cone and rod function. These findings 
likely represent increased S-cone proliferation at the expense of 
other cell types during cell fate determination. Patients typically 
develop night blindness and evidence of retinitis pigmentosa (RP). 
Autopsy studies have shown absence of rods and retinal disorgani-
zation and degeneration (57).
Among pathogenic variants in NR2E3 reported to cause ESCS, 
homozygous p.Arg311Gln variants are most common and repre-
sent a hotspot for disease among the Crypto-Jewish population 
in Portugal (58). The same change is also associated with Golg-
mann-Favre syndrome, a more severe form of ESCS (55). Variants 
in NR2E3 are also found in autosomal-recessive and -dominant 
forms of RP (59, 60). Approximately 3% of dominantly inherited 
RP is due to a heterozygous PNR mutation (p.Gly56Arg) in the first 
zinc finger of the DBD, exhibiting dominant-negative activity (60, 
61). Other variants cause altered cellular localization or homo- or 
hetero-dimerization with TLX/NR2E1 and RXRα/NR2C1 (62, 
63). Another NR, Rev-erb-α/NR1D1, has been used to potentially 
“rescue” disease progression in the rd7 mouse (64).
Chicken ovalbumin upstream promoter 
transcription factor I (NR2F1)
Chicken ovalbumin upstream promoter transcription factor I 
(COUP-TFI) is widely expressed in many tissues. It is strongly 
expressed in the brain and peripheral nervous system and has a 
potential role in regionalization of the neocortex and axonal pro-
jection. In humans, NR2F1 haploinsufficiency and de novo het-
erozygous mutations in NR2F1 have been reported in patients 
with Bosch-Boonstra-Schaaf optic atrophy syndrome (65, 66). 
Additional characteristics include developmental delay and vari-
able, nonspecific facial features. Most missense mutations (such 
as p.Arg112Lys, p.Ser113Arg, and p.Arg115Pro) cluster in the DBD 
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sulinism and macrosomia, renal proximal tubulopathy (Fanconi 
syndrome) with elevated urinary calcium, phosphate, and oxalate 
causing nephrocalcinosis has been recorded in patients with a spe-
cific HNF4α mutation (p.Arg76Trp) (82).
GWAS do show linkage of common variants around the 
HNF4A locus with T2D; a rare variant (p.Thr130Ile) in HNF4A 
confers a modest (1.2-fold) risk of T2D and is positively associated 
with HDL cholesterol levels (77).
PPARγ
PPARγ (encoded by NR1C3) is essential for adipocyte differen-
tiation but also regulates target genes that mediate triglyceride 
hydrolysis and fatty acid and glycerol uptake, together with genes 
involved in fatty acid re-esterification and lipid storage (83). 
Heterozygous, missense PPARG mutations (p. Pro467Leu, Val-
290Met), impairing its ligand-dependent transcriptional activity, 
were first identified in patients with severe insulin resistance (IR) 
and early-onset T2D (84); subsequently, the phenotype was recog-
nized to encompass a distinctive pattern of partial lipodystrophy. 
Additional features, such as hepatic steatosis and dyslipidemia, 
likely reflect an impaired ability to buffer dietary lipid load, with 
tissue lipotoxicity mediating IR. The resulting hyperinsulinemia 
mediates polycystic ovarian dysfunction and acanthosis nigricans. 
Hypertension that occurs independent of diabetic comorbidities 
is also a feature, suggesting a direct role for PPARγ in control of 
vascular tone (83).
Rare heterozygous PPARG variants associated with lipodys-
trophic IR localize to the LBD or DBD, disrupting either DNA 
binding or ligand-dependent transcription activation functions. 
Additionally, mutant receptors inhibit function of their wild-type 
counterparts in a dominant-negative manner (85). In a large, 
digenic kindred, PPARγ haploinsufficiency alone did not medi-
ate IR, but acted in concert with a PPP1R3A mutation that affects 
muscle glycogen synthesis (86). Whole exome sequencing of 
around 9,000 individuals with T2D identified nine functionally 
deleterious, rare PPARG variants that confer substantial disease 
risk; however, it could not be ascertained whether adipose mass 
was reduced in these subjects (87). A common PPARG variant 
(p.Pro12Ala) that occurs with varying frequency (2% to 18%) in 
different ethnic groups is associated with a reduction in T2D risk 
(odds ratio 0.86). Conversely, the Pro12 allele is present in 80% of 
humans and can increase population T2D risk by up to 25% (85). 
Reduced target gene activation and induction of adipogenesis by 
the Ala12 PPARγ variant may lower adipose mass and improve 
insulin sensitivity in carriers, being the basis of its protective 
effect (88). A rare variant (p.Pro113Gln) in the PPARγ aminotermi-
nal domain that exhibits gain of transcriptional function has been 
documented in four obese but paradoxically diabetic German 
subjects, but this or similar variants have not been found in other 
obese populations, suggesting a strong founder effect (85).
Small heterodimeric partner
Small heterodimer partner (SHP, encoded by NR0B2) is an atypi-
cal orphan NR that has a ligand-like binding domain with sequence 
homology to other NRs but with a truncated aminoterminal region 
that lacks a true DBD. Heterozygous NROB2 variants with a dimin-
ished ability to inhibit HNF4α function were reported in 7% of Jap-
(74). The heterozygous –1G>T variant was subsequently identified 
in an unrelated ICP case (75).
Progressive familial intrahepatic cholestasis (PFIC) comprises 
three subtypes known to be associated with mutations in trans-
port proteins (PFIC-1, encoded by ATP8B1; PFIC-2, encoded by 
ABCB11/BSEP; and PFIC-3, encoded by ABCB4), but 30% of cases 
are idiopathic. FXR variants have recently been identified in four 
children with severe neonatal cholestasis that progressed to liver 
failure that was terminal or required transplantation. A homozy-
gous premature stop mutation (p.Arg176*) abrogating DNA binding 
and function was identified in one family, and compound heterozy-
gosity for an in-frame DBD insertion (pTyr139_Asn140insLys) plus 
a 31-kb deletion encompassing the first two coding exons of NR1H4 
was identified in a second family. Similar to previous PFIC cases 
with defective bile salt export pump (BSEP, a known FXR target), 
cholestasis was associated with low/normal γ-glutamyl transferase 
levels and reduced BSEP expression. Severe vitamin K–independent 
coagulopathy, attributed to reduced FXR-dependent clotting fac-
tor levels and reduced circulating levels of other FXR-dependent 
hormones and metabolites, may represent other distinctive, diag-
nostically useful biomarkers (76).
Hepatocyte nuclear factor 4α
Hepatocyte nuclear factor 4α (HNF4α, encoded by NR2A1) con-
trols gene expression in the liver (approximately 40% of active-
ly transcribed genes) and pancreas (11% of islet cell genes) and 
regulates pathways of hepatic gluconeogenesis and pancreatic 
insulin secretion (77).
Maturity-onset diabetes of the young (MODY), usually defined 
as diabetes mellitus (diagnosed before age 25 years) with negative 
islet cell autoantibodies, is most commonly (in about 50% of cas-
es) due to mutations in HNF1α (MODY type 3), a homeobox family 
transcription factor, with HNF4A variants accounting for a further 
10% of cases (MODY type 1). Approximately 100 different hetero-
zygous mutations (58% missense, 20% frameshift or premature 
stop, 5% splice site) localizing to HNF4A coding exons have been 
recorded in this dominantly inherited disorder; a further 5% of 
variants localize to the pancreatic P2 promoter region of HNF4A, 
disrupting known tissue-specific transcription factor binding sites 
(77). Some HNF4α mutations, even those located outside the 
canonical DBD, compromise a protein interface in the HNF4α 
homodimer bound to DNA (78), with other variants disrupting 
transactivation, nuclear localization, or protein stability. Due to the 
large number of HNF4α-regulated target genes in liver and pancre-
as, it has been postulated that haploinsufficiency, with loss of even 
a fraction of functional receptor homodimers, reduces pancreatic 
glucose-dependent insulin secretion, mediating MODY (79).
In addition to a young age of diagnosis and family history of 
early-onset diabetes, reduced serum ApoA2 (known to be HNF4α 
regulated) and triglyceride levels and exquisite sensitivity to sul-
fonylurea drug therapy may be useful markers of HNF4α MODY 
(80). HNF4A mutation carriage is also associated with excess 
insulin secretion, resulting in macrosomia and neonatal hyperin-
sulinemic hypoglycemia (HH) in up to 50% of babies; the latter 
mandates neonatal surveillance of affected pregnancies because 
HH can be either mild and transient or more severe, requiring 
treatment with diazoxide (81). In addition to neonatal hyperin-
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ter diagnosis of associated disorders or providing clues to the iden-
tification of unknown orphan receptor ligands.
A subset of individuals with typical clinical or biochemical fea-
tures suggestive of disordered NR action do not have mutations in 
NR proteins, and it is possible that variants in non-coding regions 
of the genome affecting function of enhancer regions or involv-
ing epigenetic modification of chromatin or non-coding RNAs 
account for such cases. Alternatively, it is possible that defects in 
genes encoding NR cofactor proteins may be associated with such 
phenotypes. With our increasing knowledge of the human genome 
and application of high-throughput technologies to genome analy-
sis and small-molecule screening, the next 30 years are likely to be 
an equally exciting time for human NR research.
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anese patients with early-onset T2D, mild/moderate obesity, and 
increased birth weight (89). A separate study documented loss-
of-function NR0B2 variants in 2.4% (19/805) of Japanese people 
with T2D, but also found these variants in 0.8% (6/752) of controls 
without diabetes (90). In contrast, studies in different populations 
have not consistently found such high enrichment for rare SHP 
variants in cohorts with obesity or diabetes (81–94).
Conclusions
The identification of naturally occurring NR mutations over the 
last 30 years has provided insights into their structure and func-
tion, but there are still many NRs for which an associated disor-
der has not yet been discovered. Looking to the future, exome 
or genome sequencing may uncover an association of NR gene 
variants with unexpected phenotypes or disorders not readily 
predicted from their known roles in physiologic or developmen-
tal processes. In other situations, the phenotype might be subtle 
or even embryonic lethal. These technologies will also identify 
genetic variants whose functional consequences are uncertain, 
emphasizing the need to develop relevant, high-throughput 
assays of variant NR function that can accurately predict their 
pathogenic significance, as has been described recently for 
PPARG (95).
With disorders of many classical NRs associated with changes 
in hormone levels linked to their cognate ligands, it is likely that 
defects in orphan receptors are also accompanied by distinctive 
changes in circulating metabolites or proteins. Metabolomic or 
proteomic profiling of case cohorts with defined NR gene defects 
may discern characteristic biochemical signatures, enabling bet-
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